What should I know first?
During ketamine or esketamine treatment, someone may feel detached, perceive time differently or experience surroundings as unfamiliar. Staff should explain these possible effects and monitor recovery. Such effects can be uncomfortable or frightening.
Important Distinctions
A temporary drug-related experience does not by itself establish a dissociative disorder. Dissociation is an adverse effect rather than a required treatment goal, and its intensity is not proof of lasting antidepressant benefit. Persistent or unexpected symptoms need clinical assessment.
Sources and References
- Spravato: current US prescribing information (revised March 2026)
- Spravato 28 mg nasal spray: UK Summary of Product Characteristics
Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.
- Ketalar 50 mg/ml: UK Summary of Product Characteristics (text revised October 2024)
Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.
Article Information
- Edition
- United Kingdom
- Content updated
- 2026-10-19
- Sources checked
- Listed with each reference above; retained dates for shared scientific content.
- Publication status
- Published

